Perhaps it is worth adding that in first half they earnt 3% net profit margin on revenue of $62 million, which suggests a net profit of $5.4m on revenue of $180 million in FY 22. The prospectus was suggesting $130 m in FY21 and a net profit of $6.4m which is near 5% net profit margin. The prospectus seems very optimistic to me, but that suggests a PE of 9-10 if the net profit margin is 5% in FY22.
The key is where in that range of a net profit margin of 2% to 5% they can actually deliver. At the bottom they are expensive and at the top reasonably priced, though hardly cheap.
- Forums
- ASX - By Stock
- AE1
- Ann: FY22 revenue guidance of $180M fully secured
Ann: FY22 revenue guidance of $180M fully secured, page-4
Featured News
Add AE1 (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online